Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.51 |
| ▸ | AXL | P30530 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 4/20 | 0.38 |
| ▸ | DHPS | P49366 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 3/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.34 |
| ▸ | FEN1 | P39748 | 2/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20132550 | 0.80 | AXL (0.43) | TRPA1AXLIDO1NOS1DHPS | |
| SCHEMBL14804208 | 0.79 | NOS1 (0.46) | TRPA1AXLIDO1NOS1DHPS | |
| SCHEMBL21341661 | 0.76 | AXL (0.44) | TRPA1AXLIDO1NOS1DHPS | |
| SCHEMBL22967876 | 0.76 | AXL (0.56) | TRPA1AXLIDO1NOS1METAP2 | |
| SCHEMBL29769117 | 0.76 | TRPA1 (0.47) | TRPA1AXLIDO1NOS1METAP2 | |
| SCHEMBL9909086 | 0.76 | TRPA1 (0.47) | TRPA1AXLIDO1NOS1METAP2 | |
| SCHEMBL17030763 | 0.75 | AXL (0.42) | TRPA1AXLIDO1NOS1DHPS | |
| SCHEMBL31411470 | 0.75 | TRPA1 (0.50) | TRPA1AXLIDO1NOS1METAP2 | |
| SCHEMBL2627058 | 0.74 | AXL (0.68) | TRPA1AXLIDO1NOS1DHPS | |
| SCHEMBL23919008 | 0.73 | DHPS (0.42) | TRPA1AXLIDO1DHPSMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3647311-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230065217-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20220378743-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2022-12-01 | — | — | US | disclosed |
| EP-3421464-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2021-11-24 | — | — | EP | disclosed |
| US-11130749-B2 | — | — | 2021-09-28 | — | — | US | disclosed |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-10329282-B2 | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-06-25 | — | — | US | disclosed |
| US-10323023-B2 | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323023-B2 | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof | ROCK1, RHOA, ROCK2 | TRPA1 4851/4885AXL 3239/4885IDO1 3420/4885 |
| US-20230065217-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | TRPA1 1045/4885AXL 1807/4885IDO1 3980/4885 |
| US-11130749-B2 | — | ROCK1, RHOA, ROCK2 | TRPA1 4815/4885AXL 4717/4885IDO1 3951/4885 |
| US-10329282-B2 | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof | ROCK1, RHOA, ROCK2 | TRPA1 4851/4885AXL 3239/4885IDO1 3420/4885 |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | TRPA1 4790/4885AXL 2844/4885IDO1 3511/4885 |
| US-20220378743-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | SLC10A1, CYP7A1, FABP1 | TRPA1 3700/4885AXL 3892/4885IDO1 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.